anti-CD19 CAR T cells + biparatopic anti-CLEC12A bridging protein

A novel combination **cell therapy** designed for treatment of acute myeloid leukemia (AML), consisting of **anti-CD19 chimeric antigen receptor (CAR) T cells** that have been further engineered to **secrete a biparatopic anti-CLEC12A bridging protein**. The bridging protein binds to CLEC12A on leukemia cells and to the anti-CD19 CAR on the T cells, redirecting their cytotoxic activity toward CLEC12A-positive (AML) target cells. The biparatopic nature—using two distinct anti-CLEC12A antibody fragments—enhances avidity and potency. This approach aims to overcome limitations of traditional CAR T therapies targeting only B-cell antigens by redirecting them against myeloid malignancies. The combination leverages the persistence and fitness of CAR19 T cells while using a modular protein engineering platform to expand their targeting profile. The therapy is in preclinical development for relapsed/refractory AML[1][2][4][7].

Other names

CAR19 T cells secreting biparatopic anti-CLEC12A bridging proteinCAR-19 T cells secreting biparatopic anti-CLEC12A bridging proteinCAR 19 T cells secreting biparatopic anti-CLEC12A bridging proteinCLEC12A-bridging CAR19 T cellsCLEC-12A-bridging CAR19 T cellsCLEC 12A-bridging CAR19 T cells